Cumulative Index 1987

Volume 5

February	THROMBOLYSIS AND THE HEART, pages 1–146
May	EXERCISE AND THE HEART, pages 147–348
August	12-LEAD ELECTROCARDIOGRAPHY, pages 349–543
November	SPECIAL TOPICS IN CARDIOVASCULAR PHARMACOTHERAPY, pages 545–728

Note: Page numbers of issues and articles are in **boldface** type.

Acebutolol, in children, clinical experience with, 633
  renal considerations and, 683
Activated partial thromboplastin time, in monitoring coagulation system, in coronary thrombolysis, 133
Acyl plasmins, in coronary thrombolysis, 17
Acyl urokinase, in coronary thrombolysis, 17
Acylated activators, in coronary thrombolysis, 16–17
Acylated streptokinase-plasminogen complex, for coronary thrombolysis, 17
    practical considerations of, 130, 132
  for deep venous thrombosis, 115
Adenosine triphosphatase, exercise conditioning and, 262
Adenosine triphosphate, and ischemia, myocardial reperfusion and, 33, 34
Air pollution, and exercise testing, 208
Allergic reactions, due to intracoronary streptokinase, 84
  due to intravenous streptokinase, 95
Alpha-adrenergic agents, in salvage of jeopardized myocardium, after coronary thrombolysis, 71
Alpha-adrenergic stimulation, of intracellular calcium, in myocardial ischemia and reperfusion, 39–40, 42
Altitude, and exercise, 251–255
  and exercise testing, 208
Amiodarone, in pregnancy, 658–659
  renal considerations and, 683
Amoxicillin, to prevent infective endocarditis, 558
Amrinone, renal considerations and, 681
Aneurysm, left ventricular, and ST elevation, 422
Angina, unstable, coronary thrombosis in, 27–28
Angina pectoris, drugs for, and exercise, 228–230
  exercise prescription for, 203–204
  nifedipine-GITS for, 707–708
Angiography, and intracoronary streptokinase, 88
  in acute thrombotic coronary occlusion, 80–81
  in myocardial hemorrhage, due to intravenous streptokinase, 95
  pulmonary, to diagnose primary pulmonary hypertension, 567
  radionuclide, of athletic heart, in exercise, 324–325
  to assess coronary thrombolysis, 55–56
  to document coronary thrombolysis, 92–93
Angiography/angioscopy, to diagnose pulmonary embolism, 579
Angioplasty, percutaneous transluminal coronary, exercise prescription for, 205–206
Angiotensin-converting enzyme inhibitors, and exercise, in hypertension, 239, 312
  for primary pulmonary hypertension, 571
  renal considerations and, 683–684
Antiarrhythmic drugs, and exercise, 239
  and exercise testing, 207
Anticoagulation, for pulmonary embolism, 579–580
  in infective endocarditis, 555–557
  in valvular heart disease and atrial fibrillation, **591–628**
    aortic valve disease, 600
    cardioversion, 621–622
    heparin, 596–597
    incidence of thromboembolism, 597–598
    mitral annular calcification, 602
    mitral valve prolapse, 600–602
    mitral valve stenosis and regurgitation, 597–600
    mortality from thromboembolism, 598
    prevalence of, 613–614
    prosthetic valves, 117–118, 603–613
      bioprosthetic, 609–610
      mechanical, 604
      risk factors for embolic events, 604–609
    risk factors for thromboembolism, 598–599, 614–621
    warfarin. See *Warfarin*.
  long term, after coronary thrombolysis, 136
Antihypertensive drugs, and exercise, 234–239, 312–313, 316

Antihypertensive drugs *(Continued)*
neuropsychological effects of, **689–701**
materials and methods in study, 689–691
background of subjects, 689–690
case and control selection, 690
screening and testing, 690
statistical comparisons, 690–691
results of study, 691–692
Aortic valve disease, thromboembolism in, 600
Apoproteins, and exercise, in hyperlipoproteinemia, 305
in normolipemic subjects, 293
in lipid metabolism, 290–291
Arditti index, to predict infarct size and ventricular function, 437–438
Arrhythmias, and sudden death, in exercise, 338–339
cardiovascular drugs for, and exercise, 239
due to coronary thrombolysis, 134–135
with intracoronary streptokinase, 84
with intravenous streptokinase, 95
exercise testing and, 191–192
in children, beta-blockers for, 635–637
Arrhythmogenesis, in myocardial ischemia and reperfusion, 41–43
Arteriography, coronary, in hypercholesterolemia, 300
Arteriovenous oxygen difference, and dynamic exercise, 150
in coronary artery disease, 152, 153
and exercise training, 214
Aspirin, for thromboembolism, in prosthetic valves, 607, 608, 611
Atenolol, in children, clinical experience with, 631–632
in pregnancy, 663
renal considerations and, 683
Atherosclerosis, coronary. See *Coronary atherosclerosis*.
Athletic heart, and exercise, **319–329**
cardiac catheterization in, 325
echocardiogram in, 323–324
electrocardiogram in, 320–321
exercise electrocardiogram in, 321–323
physical examination in, 319–320
radionuclide angiography in, 324
rhythm abnormalities in, 325–327
tachycardia in, 327–328
time course and reversibility of changes in, 325
Atrial fibrillation, and thromboembolism, in bioprosthetic valves, 610
in cardiomyopathy, 619
in heart failure, 618–619
in hypertension, 618
in prosthetic valves, 606, 613–621
prevalence of, 613–614
risk factors for, 614–621
in thyrotoxicosis, 619–620
Atrioventricular block, first degree, and athletic heart, in *exercise, 326*
Atrium, and ventricle, during ventricular tachycardia, 512–513
Autonomic blockade, isometric exercise and, 161–162

Bacteremia, in infective endocarditis, 552–553
Bartter's syndrome, in children, beta-blockers for, 641–642
Bayes theorem, and Q waves, 364–365
Beta-blockers, and exercise, 312, 313, 316
in hypertension, 236–238
pharmacology of, 233
and exercise testing, 207
and exercise training, 219
in children, **629–649**
adverse effects of, *643–644*
effects on fetus and neonate, 629–630
for arrhythmias, 635–637
for Bartter's syndrome, 641–642
for glaucoma, 643
for growth hormone stimulation tests, 642
for hypertension, 633–635
for hypertrophic cardiomyopathy, 637–638
for Marfan's syndrome, 640–641
for migraine, 642
for pheochromocytoma, 641
for polymyoclonia, 643
for porphyria, 643
for portal hypertension, 643
for tachycardia, 636–637
for tetanus, 643
for tetralogy of Fallot, 638–640
for thyrotoxicosis, 642
potential effects on fetus and neonate, 630–633
clinical experience with, 630–633
in coronary thrombolysis, 135
in pregnancy. See *Cardiovascular drugs*.
renal considerations and, 682–683
to prevent sudden cardiac death, after coronary thrombolysis, 136
Beta-receptor antagonists, in salvage of jeopardized myocardium, after coronary thrombolysis, 71
Bioprosthetic valves, thromboembolism in, 609–610
Blood, proteolytic activity in, in coronary thrombolysis, 2–3
Blood cultures, to diagnose infective endocarditis, 546
Blood flow, coronary, dynamic exercise and, 150–151
muscle, dynamic exercise and, 151
Blood pressure. See also *Hypertension*.
arm ergometry and, 185
dynamic exercise and, 150
in coronary artery disease, 153
exercise testing and, 188–189
exercise training and, in coronary artery disease, 216
isometric exercise and, 185
in impaired left ventricular function, 162
in myocardial ischemia, 163
isometric exercise training and, in normal subjects, 165, *166*
vasodilators and, in exercise, 238
Bradycardia, resting sinus, and athletic heart, in exercise, 325–327
Breasts, tumors of, and malignant pericardial disease, 583
Bretylium, renal considerations and, 683
Bruce protocol, for treadmill exercise, 147, 175, 184

Cabrera's sign, in myocardial infarction, 395, 396, 397
during ventricular pacing, 408–410
Calcium, role of, in myocardial ischemia and reperfusion, 38–40
Calcium antagonists, pharmacology of, and exercise, 233–234
Calcium channel blockers, and exercise testing, 207
for primary pulmonary hypertension, 571
in coronary thrombolysis, 135
in salvage of jeopardized myocardium, after coronary thrombolysis, 70–71
renal considerations and, 683
Captopril, and exercise, in hypertension, 239, 312
renal considerations and, 684
Carbon 11 (11C-palmitate), in myocardial reperfusion, after coronary thrombolysis, 69

Cardiac arrest, exercise and. See *Sudden death.*
Cardiac catheterization, in malignant pericardial disease, 587
of athletic heart, in exercise, 325
to diagnose primary pulmonary hypertension, 567
Cardiac glycosides, in pregnancy, 652–654
Cardiac output, and aging heart, in exercise, 333
exercise and, in high altitudes, 252
Cardiac tamponade, in malignant pericardial disease, 585–586
Cardiac transplantation, exercise prescription for, 206
Cardiomyopathy, and atrial fibrillation, thromboembolism in, 619
hypertrophic, in children, propranolol for, 637–638
Q waves in, 362–363
ventricular tachycardia in, 530–531
Cardiovascular drugs, and exercise, **227–244**
in arrhythmias, 239
in coronary artery disease, 227–230
effort angina pectoris, 228–230
spontaneous angina pectoris, 230
unstable angina pectoris, 230
in heart failure, 239–240
in hypertension, 234–239
angiotensin-converting enzyme inhibitors, 239
beta-blockers, 236–238
central alpha-agonists, 236
diuretics, 235–236
hemodynamics of, 234–235
vasodilators, 238–239
pharmacology of antianginal agents, 230–234
beta-blockers, 233
calcium antagonists, 233–234
nitrates, 230–232
transdermal nitroglycerin, 232–233
in pregnancy, **651–674**
antiarrhythmics, 654–660
amiodarone, 658–659
disopyramide, 655–656
lidocaine, 656–657
mexiletine, 657–658
procainamide, 654–655
quinidine, 654
verapamil, 659–660
beta-blockers, 660–665
atenolol, 663
clinical experience, 661–664
influence on maternal-fetal physiology, 660–661
labetalol, 664
metoprolol, 662–663
pindolol, 663–664
propranolol, 661–662
cardiac glycosides, 652–654
hydralazine, 666–667
nitrates, 667–668
sodium nitroprusside, 665–666
renal considerations and, **675–688**
angiotensin-converting enzyme inhibitors, 683–684
antiarrhythmics, 681–683
estimating level of renal function, 675–680
for drug dosage, 680
in acute renal failure, 677
in chronic renal failure, 676–677
in dialysis, 677, 679
inotropic agents, 680–681
Cardiovascular medicine, drug delivery systems in. See *Clonidine-TTS; Nifedipine-GITS.*
Cardioversion, anticoagulation and, in valvular heart disease and atrial fibrillation, 621–622
Catecholamines, and exercise training, in coronary artery disease, 216
Catheterization, cardiac, after coronary thrombolysis, 136
in malignant pericardial disease, 587
of athletic heart, in exercise, 325
to diagnose primary pulmonary hypertension, 567
Central alpha-agonists, and exercise, in hypertension, 236
Cerebral edema, high altitude, clinical features of, 254, 255
Cerebral hemorrhage, hypertension and, exercise and, 315
Chapman's sign, in myocardial infarction, 395, 396, 397
during ventricular pacing, 414
Chemotherapy, for malignant pericardial disease, 588
Cholesterol, total, exercise and, in normolipemic subjects, 292
Chronic obstructive pulmonary disease, Q waves in, 360–361
Circulation, regional, hyperthermia and, 248
in dynamic exercise, 150–151
in exercise testing, 180
Clauss procedure, for monitoring coagulation system, in coronary thrombolysis, 133
Clonidine, and exercise, in hypertension, 236
renal considerations and, 684
Clonidine-TTS, 708–714
adverse effects of, 713
clinical pharmacology of, 709
clinical trials of, 711–712
description of system, 709–710
dose and administration of, 712
pharmacokinetics of, 710–711
Clots, lysis of. See specific types, e.g., *Deep venous thrombosis.*
Coagulation system, monitoring of, in coronary thrombolysis, 133–134
Cold temperature, and exercise testing, 208
Conduction disorders, unstable intraventricular, 489–497
bradycardia-dependent block, 492–494
rate-independent blocks, 494–496
tachycardia-dependent blocks, 489–492
Congenital heart disease, exercise testing and, 190
Congestive heart failure, management of, after coronary thrombolysis, 137
Cor pulmonale, Q waves in, 361
Coronary arteriography, in hypercholesterolemia, 300
Coronary artery bypass grafting, in salvage of jeopardized myocardium, after coronary thrombolysis, 72
Coronary artery bypass surgery, and hemodynamic *response to exercise, 152–153*
exercise prescription for, 204–205
reappearance of electrical forces after, 371–372
Coronary artery disease, and atrial fibrillation, thromboembolism in, 617–618
and cardiovascular responses to exercise, 151–154
and sudden death, in exercise, 342
coronary collaterals in, exercise conditioning and, 265
drugs for, and exercise, 227–230
exercise training and, **211–225**
benefits of, 215–217
psychologic, 214–215
beta-blockers and, 219
cardiac response in coronary disease patients, 213–214
cardiac response in normal subjects, 212–213
designing prescription for, 220–221
early postinfarction, 219–220
exercise required for effect, 217–219
peripheral response to, 214
safety of, 221
sexual activity and, 217
types of exercise, 211–212
transient Q waves in. See *Q waves.*
ventricular tachycardia in, 531–535

Coronary atherosclerosis, and thrombosis, underlying *myocardial infarction*, **21–30**
cause-and-effect relationships in evaluations, 26–27
clinicopathologic correlations of, 23
etiology and pathogenesis of occlusive coronary artery disease, 22–23
pathogenesis of coronary thrombosis, *23–24*
results of postmortem and clinical evaluations, 24–26
unstable angina and sudden cardiac death in evaluations, 27–28
Coronary capacitance, exercise conditioning and, 263–265
Coronary collaterals, and chronic ischemia, exercise conditioning and, 265–267
Coronary heart disease, exercise and, epidemiology of, **271–283**
adherence issues in, 281
implications for practitioner in, *281*
national trends for exercise participation in, 280–281
occupation in, 271
reducing exercise risks in, 277–279
risk factors in, 272–273
risk of exercise participation in, *275–276*
risk of exercise testing in, 273–274
Coronary thrombolysis, acylated activators in, 16–17
assessment of, **55–66**
coronary angiography in, 55–56
creatine kinase activity in plasma, for estimation of infarct size, 57–58
creatine kinase time activity curves in, *56–57*
electrocardiography in, 56
infarct imaging in, 61–62
plasma MM CK isoforms in, for potential detection of reperfusion, 58–59
positron-emission tomography in, *62–63*
thallium-201 scintigraphy in, 60–61
ventricular function in, 59–60
clinical pharmacology of, **125–128**
documentation of, 92–93
effects of, *50–52*
emergence of, **49–53**
myocardial infarction in, 49–50
fibrinolytic system in. See *Fibrinolytic system.*
for prosthetic valve thrombosis, 117–118
plasmin vs. plasminogen activators in, *6–7*
practical considerations in, **129–141**
administration of specific agents, 131–133
choice of fibrinolytic agent, 130–131
early management of candidates, 133
health care system, *137*
management after thrombolysis, 135–136
measures to enhance salvage of myocardium, 135
monitoring of coagulation system, 133–134
patient selection, 51–52, 129–130
prevention of sudden death and reinfarction, *136–137*
routes of administration, 131
use of lidocaine, 135
salvage of jeopardized myocardium after, **67–77**
adjunctive pharmacologic therapy in, 70–71
future directions in, *72*
management of residual stenosis and reocclusion in, 71–72
rationale underlying, 67–68
temporal dependence of, 68–70
selection of thrombolytic agent for, *102–103*
successful, reocclusion after, 83
transient Q waves and, 370–371
with combined intravenous and intracoronary streptokinase, 82
with intracoronary streptokinase. See *Streptokinase.*
with intravenous streptokinase. See *Streptokinase.*
with tissue-type plasminogen activator. See Tissue-type plasminogen activator (t-PA).
with urokinase. See *Urokinase.*
Coumadin, after coronary thrombolysis, 136
for pulmonary embolism, 580
for thromboembolism, in bioprosthetic valves, *611*, *612*
Creatine kinase, plasma activity of, to assess infarct size, in coronary thrombolysis, 57–58, 96
to diagnose myocardial infarction, 134
time activity curves of, to assess coronary thrombolysis, *56–57*

Deep venous thrombosis, lysis of, 113–115
acylated plasminogen-streptokinase complex in, 115
streptokinase in, 113–115
tissue-type plasminogen activator in, 115
urokinase in, *115*
recommendations for treatment of, 115
Dextran, to prevent pulmonary embolism, 581
Dialysis, cardiovascular drugs and, 677, 679
Diazoxide, for primary pulmonary hypertension, 569
Digitalis, pharmacology of, and exercise, *240*
renal considerations and, 680
Digitoxin, renal considerations and, 680–681
Digoxin, in pregnancy, 652–654
renal considerations and, 680
Diltiazem, for primary pulmonary hypertension, *571*
pharmacology of, and exercise, 234
renal considerations and, *683*
Dipyridamole, for thromboembolism, in prosthetic valves, 606–607, 608
Disopyramide, in pregnancy, 655–656
renal considerations and, 681
Diuretics, pharmacology of, and exercise, 235–236, 312
Doppler echocardiography, to diagnose primary pulmonary hypertension, 566–567
to diagnose prosthetic valve endocarditis, 554
Doppler ultrasonography, to diagnose pulmonary embolism, 578–579
Drug delivery systems, in cardiovascular medicine. See *Clonidine-TTS; Nifedipine-GITS.*
Drugs, antiarrhythmic, and exercise testing, 207
to predict risk of rapid rates during atrial fibrillation, *506*
antihypertensive. See *Antihypertensive drugs.*
and exercise, 312–313, 316
cardiovascular. See *Cardiovascular drugs.*
therapeutic, evaluation of, exercise testing in, 180
Dysplasia, arrhythmogenic right ventricular, *530*
Dyspnea, exertional, pathophysiology of, 172–174

Echocardiography, of athletic heart, in exercise, 323–324
to assess Q waves, 364
to detect left ventricular hypertrophy, 459–460
vs. electrocardiography, *460–461*
to diagnose infective endocarditis, 546, 550–551
to diagnose primary pulmonary hypertension, 566–567
to diagnose prosthetic valve endocarditis, 554
Ectopy, exercise training and, in coronary artery disease, 216
Edema, high altitude, clinical manifestations of, 254, 255
Electrocardiography, and exercise, in high altitudes, 252
in hyperthermia, 247
in hypothermia, 249
of athletic heart, 320–323

and exercise testing, 184, 185, 186
historical aspects of, **349–355**
Alexander Samojloff and, 351
Augustus Waller and, 349–350
early manufacturers and, 352
Georg Nicolai and, 351–352
Sir Thomas Lewis and, 352–353
William Craib and, 353–354
William Einthoven and, 350–351
in patient selection, for coronary thrombolysis, 129–130, 134–135
in reperfusion. See Myocardial reperfusion.
in thallium stress testing, 186
in ventricular tachycardia. See *Ventricular tachycardia.*
in Wolff-Parkinson-White syndrome. See *Wolff-Parkinson-White syndrome.*
to assess coronary thrombolysis, 56
to assess myocardium, in coronary thrombolysis, 95–96
to diagnose malignant pericardial disease, 585
to diagnose myocardial infarction. See *Myocardial infarction.*
to diagnose ventricular hypertrophy, **455–467**
criteria for left ventricular hypertrophy, 456–457
echocardiography to detect left ventricular hypertrophy, 459–460
in presence of left bundle branch block, 462–463
in presence of right bundle branch block, 461–462
results in combined ventricular hypertrophy, 464–465
results in left ventricular hypertrophy, 457–458
results in right ventricular hypertrophy, 463–464
sensitivity in relation to etiology of cardiac disease, 458–459
total QRS voltage as criterion, 459
vs. echocardiography to detect left ventricular hypertrophy, 460–461
to evaluate ischemic and infarcted myocardium, **447–454**
comparisons with other methods, 449–450
new recording methods, 450
quantitative changes, 452–453
in early coronary care, 450, 452
steps to comprehensive scoring system, 447–448
Electrophysiology, alterations in, in myocardial ischemia and reperfusion, 41–43
Ellis procedure, for monitoring coagulation system, in coronary thrombolysis, 133–134
Embolectomy, for pulmonary embolism, 581
Embolism, coronary, in infective endocarditis, 552
pulmonary. See *Pulmonary embolism.*
Enalapril, and exercise, in hypertension, 239, 312
renal considerations and, 684
Encainide, renal considerations and, 682
Endocarditis, infective. See *Infective endocarditis.*
Enterococci, and infective endocarditis, 549
Environmental conditions, for exercise, **245–258**
altitude, 251–255
altitude illness, 253–255
thermoregulation, 245–251
hyperthermia, 245–248
hypothermia, 248–251
Enzymatic:serum CK-MB, vs. electrocardiography, to estimate myocardial infarction, 449
Enzymes, and exercise, in hyperlipoproteinemia, 305
in lipid metabolism, 291
in normolipemic subjects, 293–294
Ergometry, arm, in exercise prescription, 202
protocol for, 185
Euglobulin lysis time, for monitoring coagulation system, in coronary thrombolysis, 134
Exercise, and aging heart, **331–336**
and antihypertensive drugs, 312–313, 316
and athletic heart. See Athletic heart.
and cardiovascular drugs. See *Cardiovascular drugs.*
and coronary heart disease. See *Coronary heart disease.*
and failing heart, **171–181**
exercise testing for, 174–179
interpretation of, 179–180
protocols for, 174–175
respiratory gas analysis in, 177–178
exertional dyspnea and fatigue in, pathophysiology of, 172–174
hemodynamic, metabolic, and symptomatic responses to, 172
physiology of, 171–174
and hypertension. See *Hypertension.*
and Q waves, 374–376
and sudden death. See *Sudden death.*
dynamic, cardiovascular responses to, **147–156**
arteriovenous oxygen difference, 150
coronary artery disease and, 151–154
heart rate, 147–149
hemodynamic response, 150
regional circulation, 150–151
stroke volume, 149
physiology of, 212
environmental conditions for. See Environmental conditions.
isometric, cardiovascular responses to, **157–170**
autonomic blockade, 161–162
cardiovascular disease and, 162–165
hypertension, 164–165
impaired left ventricular function, 162–163
myocardial ischemia, 163
valvular heart disease, 163–164
cardiovascular regulation, 160–161
dynamic exercise, 157–158
exercise intensity, 159–160
isometric exercise training, 165–168
in cardiac patients, 166–168
in normal subjects, 165–166
physiology of, 211–212
Exercise conditioning, adaptations to, **259–270**
coronary vasculature, 263–267
collateral development during chronic ischemia, 265–267
coronary capacitance, 263–265
muscle structure and function, 259–263
biochemistry, 262–263
diastolic function, 262
hypertrophy, 260–261
systolic function, 261–262
pathologic hypertrophy, 267
Exercise prescriptions, cardiac medications and, 207
components of, 198–203
aerobic conditioning, 198
duration, 200
frequency, 198–199
intensity, 199–200
mode of activity, 200–203
warm-up and cool-down, 198
environmental considerations and, 207–208
for angina pectoris, 203–204
for angioplasty, 205–206
for cardiac transplantation, 206
for coronary artery disease, 220–221
for myocardial infarction and cardiac surgery, 204–205
for pacemaker recipients, 206–207
guidelines for, **197–210**
medical evaluation and, 197–198

Exercise testing, and aging heart, 341–342
and failing heart, 174–179
interpretation of, 179–180
protocols for, 174–175
respiratory gas analysis in, 177–179
in coronary heart disease, need for, 278–279
risks of, 274–275
in exercise prescription, for competitive sports, 189–192
arrhythmias and, 191–192
congenital heart disease and, 190
ischemic heart disease and, 191
valvular heart disease and, 190–191
for sports, **183–196**
exercise training and cardiac rehabilitation, 192–193
interpretation of, 186–189
electrocardiographic, 186–188
functional capacity, 189
hemodynamic, 188–189
protocols for, 183–186
arm ergometry, 185
bicycle, 184–185
isometric, 185
thallium stress testing, 185–186
treadmill, 184
safety of, 186
Exercise training, in coronary artery disease. See *Coronary artery disease.*
in hyperlipoproteinemia. See *Hyperlipoproteinemia.*
in hypertension, 313–315
isometric, 165–168
in cardiac patients, 166–168
in normal subjects, 165–166
Extrasystoles, atrial, to assess accessory pathway refractory period, in Wolff-Parkinson-White syndrome, 506
ventricular, in myocardial infarction, during ventricular pacing, 416

Fascicular blocks, diagnosis of, recent advances in, **469–488**
blocks produced by intra His bundle lesions, 483–484, 486
intraventricular focal block, 473–474
left anterior block and left ventricular hypertrophy, 479
left anterior block with complete right bundle branch block, 476
left anterior block with left ventricular focal block, 474–476
left anterior block with myocardial infarction, 476–477
left anterior block without q waves in leads I and aVL, 477, 479
left anterior hemiblock with electrical axis in right superior quad rant, 479
left middle block, 487
left posterior block, 480
left posterior block with myocardial infarction, 480, 483
pure left anterior fascicular block, 470–473
Fatty acids, nonesterified, in myocardial ischemia and reperfusion, 34–35
Fibrinogen leg scanning, to diagnose pulmonary embolism, 578
Fibrinolysin, in coronary thrombolysis, 4
Fibrinolysis, in infective endocarditis, 556
pharmacologic activation of, in coronary thrombolysis, clinical use of, 7–10
early animal studies of, 6
plasminogen activator vs. plasmin in, 6–7
streptococcal, in coronary thrombolysis, 3–4
tissue, in coronary thrombolysis, 2
Fibrinolytic system, constituents of, 51
pharmacologic activation of, for coronary thrombolysis, **1–11, 13–19**
discovery of, 1–4
early studies of fibrin dissolution in vivo, 4–6
Fibrinopeptide A, for monitoring coagulation system, in coronary thrombolysis, 134
Fick equation, for oxygen consumption, 147
First degree atrioventricular block, and athletic heart, in exercise, 326
Flecainide, renal considerations and, 682
Frank-Starling mechanism, and stroke volume, in dynamic exercise, 149
Free radicals, in salvage of jeopardized myocardium, after coronary thrombolysis, 71
production of, in myocardial ischemia and reperfusion, 40–41

Glaucoma, in children, beta-blockers for, 643
Glycolytic flux, in myocardial ischemia and reperfusion, 34
Graded exercise tolerance test, and exercise testing, 197–198
Growth hormone stimulation tests, in children, beta-blockers for, 642
Guanabenz, and exercise, in hypertension, 236

Heart, aging, exercise and, **331–336**
athletic. See *Athletic heart.*
Heart and lung transplantation, for primary pulmonary hypertension, 573
Heart failure, and atrial fibrillation, thromboembolism in, 618–619
drugs for, and exercise, 239–240
Heart rate, and aging heart, in exercise, 333
in arm ergometry, 202
in dynamic exercise, 147–149
in exercise, hypertension and, 234–235
hyperthermia and, 247
in high altitudes, 252
in exercise testing, beta-blockers in, 207
for cardiac transplantation, 206
for pacemaker recipients, 206–207
heat stress and, 207–208
in high altitudes, 208
monitoring of, 199–200
in exercise training, 218
Heat stress, and exercise testing, 207–208
Hemorrhage, cerebral, hypertension and, exercise and, 315
myocardial, clot-selective activators and, 130
due to intracoronary streptokinase, 83–84
due to intravenous streptokinase, 95
due to tissue-type plasminogen activator, 106
myocardial reperfusion and, 32
warfarin therapy and, 595–596
Heparin, after coronary thrombolysis, 135–136
for anticoagulation, 596–597
for mural thrombosis, 120
for pulmonary embolism, 579–580
vs. streptokinase, for deep venous thrombosis, 113–115
His bundle, lesions of, and fascicular blocks, diagnosis of, 483–484, 486
Hydralazine, and exercise, in hypertension, 238
for primary pulmonary hypertension, 570–571

in pregnancy, 666–667
renal considerations and, 684–685
Hypercholesterolemia, exercise and, 297–302
Hyperlipidemia, exercise and, 294–302
Hyperlipoproteinemia, exercise and, apoproteins in, 305
enzymes in, 305
in hypercholesterolemia, 297–302
in hypertriglyceridemia, 294–297
in normolipemic subjects, 292–294
vs. hyperlipidemia, 294–302
insulin in, 304–305
exercise training and, **285–310**
classification of plasma lipids, 286
clinical importance of plasma lipids, 285–286
review of lipid metabolism, 286–292
definitions, 287
function, 289–291
mechanistic models, 291–292
particle composition, 287, 289
Hypertension. See also *Blood pressure.*
and atrial fibrillation, thromboembolism in, 618
drugs for. See *Antihypertensive drugs.*
exercise and, **311–318**
advice to patients, 315–316
cardiovascular responses in, 311–312
exercise training in, 313–315
risk of sudden death and, 315
in children, beta-blockers for, 633–635
isometric exercise and, 164, 164–165
management of, after coronary thrombolysis, 136–137
nifedipine-GITS for, 705, 707
portal, in children, beta-blockers for, 643
primary pulmonary. See *Primary pulmonary hypertension.*
Hyperthermia, and exercise, 245–248
Hypertriglyceridemia, exercise and, 294–297
Hypertrophy, cardiac, exercise conditioning and, 260, 267
left ventricular, isometric exercise training and, in normal subjects, 165–166
ventricular, electrocardiographic diagnosis of. See *Electrocardiography.*
Hypotension, due to intravenous streptokinase, 95
systolic, exercise testing and, 189
Hypothermia, and exercise, 248–251

Idioventricular rate, in myocardial ischemia and reperfusion, 42
Impedance plethysmography, to diagnose pulmonary embolism, 578
Infarction, subendocardial, and coronary atherosclerosis, 23
Infective endocarditis, **545–562**
anticoagulation in, 555–557
diagnosis of, 545–546
due to *Staphylococcus aureus*, therapy for, 549–550
enterococcal, therapy for, 549
indications for surgery, 550–559
active endocarditis, 553–554
emboli, 552
myocardial invasion, 551–552
prosthetic valve endocarditis, 554–555
refractory infection, 552–553
role of echocardiography in, 550–551
valvular damage, 551
nonenterococcal streptococcal, therapy for, 547, 549
prophylaxis for, 557–559
therapy for, 546–550
Inferior vena cava filter, for pulmonary embolism, 581
Inflammatory response, to myocardial reperfusion, 37–38
Insulin, and exercise, in hyperlipoproteinemia, 304–305
Ischemia, chronic, coronary collaterals in, exercise conditioning and, 265–267
myocardial, isometric exercise and, 163
myocardial reperfusion and. See *Myocardial reperfusion.*
Ischemic heart disease, exercise testing and, 191
Isomyosins, exercise conditioning and, 262
Isoproterenol, for primary pulmonary hypertension, 569
in pregnancy, 661

Karvonen method, to measure heart rate reserve, in exercise testing, 199
to measure training systolic blood pressure, in exercise prescription, 206
Kidney function, cardiovascular drugs and. See *Cardiovascular drugs.*

Labetalol, in children, clinical experience with, 633
for pheochromocytoma, 641
in pregnancy, 664
renal considerations and, 683
Lactate, systemic levels of, in exercise, 172
in exercise testing, 177–179
Laser angioplasty, in salvage of jeopardized myocardium, after coronary thrombolysis, 72
Left anterior hemiblock, and vectorcardiography, to diagnose myocardial infarction, 382–384, 388–389
Q waves in, 360
with electrical axis in right superior quadrant, 471
with left ventricular focal block, diagnosis of, 474–476
Left bundle branch block, and myocardial infarction, diagnosis of. See *Myocardial infarction.*
left ventricular hypertrophy with, 462–463
Q waves in, 358–360
Left ventricular ejection fraction, vs. electrocardiography, to estimate myocardial infarction, 449
Left ventricular function, impaired, and isometric exercise, 162–163
Left ventricular hypertrophy, and isometric exercise training, in normal subjects, 165–166
left anterior fascicular block and, diagnosis of, 471
Leukemia, and malignant pericardial disease, 584
Lidocaine, in coronary thrombolysis, 135
in pregnancy, 656–657
renal considerations and, 681–682
Lipids, plasma, classification of, 286
clinical importance of, 285–286
metabolism of. See *Hyperlipoproteinemia.*
serum, exercise training and, in coronary artery disease, 216
Lipoproteins, and exercise, in normolipemic subjects, 292–293
Lisinopril, renal considerations and, 684
Longevity, exercise training and, in coronary artery disease, 216–217
Lorcainide, renal considerations and, 682
Lower extremities, studies of, to diagnose pulmonary embolism, 578–579
Lung biopsy, to diagnose primary pulmonary hypertension, 567
Lungs, tumors of, and malignant pericardial disease, 583

Magnetic resonance imaging, to diagnose primary pulmonary hypertension, 567

Marfan's syndrome, in children, beta-blockers for, 640–641
Mean arterial pressure, dynamic exercise and, 158
isometric exercise and, 158–159
Metabolic equivalents, in exercise testing, 175, 189, 192–193, 200
Metabolism, changes in, in myocardial ischemia and reperfusion, 33–35
Methyldopa, and exercise, in hypertension, 236, 312, 313
neuropsychological effects of. See *Antihypertensive drugs.*
renal considerations and, 684
Metoprolol, and exercise, in hypertension, 237
in children, clinical experience with, 631
for hypertension, 634
for tachycardia, 636
in pregnancy, 662–663
renal considerations and, 682
Mexiletine, in pregnancy, 657–658
renal considerations and, 682
Minoxidil, and exercise, in hypertension, 238
renal considerations and, 685
Mitral annular calcification, thromboembolism in, 602
Mitral valve prolapse, and infective endocarditis, prophylaxis for, 557–558
thromboembolism in, 600–602
ventricular tachycardia in, 530
Mitral valve stenosis and regurgitation, anticoagulation in, 597–600
risk factors for thromboembolism in, 598–599
Mountain sickness, clinical features of, 254
Mural thrombosis, lysis of, 120–121
management of, after coronary thrombolysis, 137
Muscles, structure and function of, in exercise conditioning. See *Exercise conditioning.*
Myocardial infarction, and coronary thrombolysis, 49–50
anterior, diagnostic advances in, 389–390
during ventricular pacing, electrocardiographic diagnosis of, 404–410
Cabrera's sign in, 408–410
St-qR pattern in, 405–407
waves in leads I and aVL, 404–405
coronary atherosclerosis and thrombosis underlying. See *Coronary atherosclerosis.*
diagnostic advances in, **381–392**
vectorcardiography in, 382–384
during ventricular pacing, electrocardiographic diagnosis of, **403–417**
Chapman's sign in, 414
ST-T wave abnormalities in, 415
ventricular extrasystoles in, 416
early exercise training after, 219–220
exercise prescription for, 204–205
imaging of, to assess coronary thrombolysis, 61–62
in presence of left bundle branch block, diagnosis of, **393–401**
early electrocardiographic studies in, 393–394
myocardial perfusion imaging in, 395–398
inferior, diagnostic advances in, distance and velocity criteria in, 386–388
in presence of left anterior hemiblock, 388–389
spatial-contour criteria in, 384–386
terminal forces criteria in, 386
inferior wall, during ventricular pacing, electrocardiographic diagnosis of, 410–412
morphologic patterns in aVR, 411–412
lateral, diagnostic advances in, 390–391
left posterior fascicular block with, diagnosis of, 480, 483
posterior, diagnostic advances in, 391–392
posterior wall, and dominant R waves in lead V1, electrocardiographic diagnosis of, 413
right ventricular, electrocardiographic diagnosis of, 414
size of, estimation of, creatine kinase plasma activity in, 57–58, 96
myocardial reperfusion and, 84–86
ST abnormalities in, **419–425**
persistent ST elevation, 421–422
reciprocal changes, 419–421
right ventricular infarction, 422–424
Q waves in right precordial leads, 423–424
ST elevation in right precordial leads, 423
unusual electrocardiographic presentations, 424
transient Q waves in. See *Q waves.*
ventricular tachycardia and, QRS-wave form in, 531–535
with left anterior fascicular block, diagnosis of, 476–477
Myocardial ischemia, isometric exercise and, 163
Myocardial reperfusion, and ischemia, biochemical and morphologic changes in, 33–38
aerobic metabolism, 33–34
anaerobic metabolism, 34
intermediary metabolism, 34–35
role of calcium in, 38–40
structural correlates of, 35–38
and myocardial hemorrhage, 32
assessment of, creatine kinase time activity curves in, 56–57
contractile function changes in, 32–33
electrocardiographic effects of, **427–445**
evolution of myocardial infarction patterns, 427–428
limitations of standard bedside electrocardiogram, 432–434
on late potentials after myocardial infarction, 438–443
on scoring systems, 434–438
reliability of QRS scores to predict response to reperfusion, 436–438
standard changes, 428–432
influence of, on infarct size and left ventricular function, 84–86
ischemia and, 31–32
limitations and hazards of, 38–43
electrophysiologic alterations and arrhythmogenesis, 41–43
free radicals and myocardial injury, 40–41
limitations to, 32
pathophysiology of, **31–48**
potential detection of, plasma MM CK isoforms in, 58–59
rationale underlying, 31
transient Q waves and, 370–371
Myocardial stunning, transient Q waves and, 369–370
Myocardium, hibernating, transient Q waves and, 372
ischemic and infarcted, evaluation of. See *Electrocardiography.*

Nadolol, renal considerations and, 684
Naughton protocol, for treadmill exercise, 175, 184
Nifedipine, for primary pulmonary hypertension, 571
pharmacology of, and exercise, 234
renal considerations and, 683
Nifedipine-GITS, 703–708
bioavailability of, 704–705
clinical experience with, 705, 707–708
delivery rate of, 704
pharmacokinetics of, 704
Nitrates, in pregnancy, 667–668
pharmacology of, and exercise, 230–232
renal considerations and, 685

Nitroglycerin, intravenous, in coronary thrombolysis, 135
transdermal, pharmacology of, and exercise, 232–233
Nitroprusside, renal considerations and, 685
"No reflow" phenomenon, in myocardial reperfusion, 32
in salvage of jeopardized myocardium, after coronary thrombolysis, 68–69

Obesity, and hypertension, exercise in, 314–315
Occlusion, subtotal coronary, and coronary thrombolysis, 81–82
Orthopedic injuries, risks of, in exercise, 276
Oxprenolol, in children, clinical experience with, 632
Oxygen consumption, arm ergometry and, 185, 202
exercise and, and aging heart, 331–333
and failing heart, 172
beta-blockers in, 238
in high altitudes, 252
in hypertriglyceridemia, 296
exercise testing and, 189, 199–200
and failing heart, 174, 175, 177–179, 179–180
Fick equation for, 147
isometric exercise and, 158, 159, 185
isometric exercise training and, in cardiac patients, 167
myocardial, exercise testing and, 203
exercise training and, in coronary artery disease, 215–216

Pacemakers, and infective endocarditis, prophylaxis for, 558–559
exercise prescription for, 206–207
Penicillin, for nonenterococcal streptococcal endocarditis, 547, 549–550
for staphylococcal endocarditis, 549–550
Penn-cube formula, of left ventricular mass, 459–460
Pentoxifylline, for thromboembolism, in prosthetic valves, 608
Percutaneous transluminal coronary angioplasty, exercise prescription for, 205–206
in arterial and arteriovenous shunt thrombosis, 120
in salvage of jeopardized myocardium, after coronary thrombolysis, 71–72
to prevent reocclusion, after successful coronary thrombolysis, 81
Perfusion imaging, myocardial, evaluation of electrocardiographic criteria by, 395–398
Pericardial disease, malignant, **583–589**
clinical features of, 585
diagnosis and differentiation of, 585–587
incidence and etiology of, 583–584
mechanism of, 584–585
prognosis for, 589
therapy for, 587–589
Pericardial fluid, analysis of, in malignant pericardial disease, 587
Pericardiocentesis, for malignant pericardial disease, 587–588
Pericarditis, in malignant pericardial disease, 586–587
Phentolamine, for primary pulmonary hypertension, 569
Pheochromocytoma, in children, beta-blockers for, 641
Phospholipids, in lipid metabolism, 287
Pindolol, in pregnancy, 663–664
renal considerations and, 682
Plaques, atherosclerotic, histologic features of, 21–22
in coronary thrombosis, 23–24
Plasma assays, to measure heparin action, in anticoagulation, 597
Plasma lipids, classification of, 286
clinical importance of, 285–286
metabolism of. See *Hyperlipoproteinemia.*
Plasma MM CK isoforms, analysis of, for potential detection of reperfusion, in coronary thrombolysis, 58–59
Plasmin, clinical pharmacology of, 125, 126
in coronary thrombolysis, 4
vs. plasminogen activator, 6–7
Plasminogen activators, vs. plasmin, in coronary thrombolysis, 6–7
Platelet suppressive therapy, for thromboembolism, in prosthetic valves, 606–609
Pollution, air, and exercise testing, 208
Polymyoclonia, in children, beta-blockers for, 643
Porphyria, in children, beta-blockers for, 643
Positron-emission tomography, in salvage of jeopardized myocardium, after coronary thrombolysis, 69
to assess coronary thrombolysis, 62–63
Potassium, serum, and exercise, in hypertension, 236
Prazosin, and exercise, in hypertension, 238
renal considerations and, 685
Pre-excitation, intermittent, in Wolff-Parkinson-White syndrome, 505–506
Pregnancy, cardiovascular drugs in. See *Cardiovascular drugs.*
pharmacologic considerations in, 651–652
Primary pulmonary hypertension, **563–576**
diagnosis of, 565–568
etiology of, 564–565
pathology of, 563–564
survival rates in, 567–568
therapy for, 568–573
Procainamide, in pregnancy, 654–655
renal considerations and, 681
Propranolol, and exercise, in hypertension, 237–238
in children, adverse effects of, 643–644
clinical experience with, 630–631
for Bartter's syndrome, 641–642
for growth hormone stimulation tests, 642
for hypertension, 634–635
for hypertrophic cardiomyopathy, 637–638
for Marfan's syndrome, 640–641
for migraine prophylaxis, 642
for pheochromocytoma, 641
for polymyoclonia, 643
for porphyria, 643
for portal hypertension, 643
for tachycardia, 636–637
for tetanus, 643
for tetralogy of Fallot, 639–640
for thyrotoxicosis, 642
in pregnancy, 661–662
neuropsychological effects of. See *Antihypertensive drugs.*
renal considerations and, 682
Prostacyclin, for primary pulmonary hypertension, 570
Prosthetic valves, and infective endocarditis, 554–555
in valvular heart disease and atrial fibrillation. See *Anticoagulation.*
thrombosis of, lysis of, 117–118, 603–613
Protein C, in anticoagulation, 592–593
Protein S, in anticoagulation, 592
Prothrombin time, in anticoagulation, 593–594
Prourokinase (scu-PA), for coronary thrombolysis, practical considerations of, 14–15, 130, 132–133
Pulmonary artery pressures, exercise and, in high altitudes, 252
Pulmonary edema, high altitude, clinical features of, 254, 255

Pulmonary embolism, **577–582**
diagnosis of, 577–579
prophylaxis for, 581
risk factors for, 577
therapy for, 115–117, 117, 579–581
anticoagulants, 579–580
embolectomy, 581
inferior vena cava filter, 581
thrombolytic agents, 580–581
streptokinase, 116–117
tissue-type plasminogen activator, 117
urokinase, 116

Q waves, exercise-induced, 374–375
in right precordial leads, as sign of right ventricular infarction, 423–424
normal and noninfarct, **357–366**
Bayes theorem and, 364–365
differential diagnosis of, 363–364
physiology and pathophysiology of, 357–363
altered conduction and, 358–360
myocardial damage and replacement and, 363
positional factors and, 358
ventricular enlargement and, 360–363
rate-dependent, and right bundle branch block-dependent, in anteroseptal myocardial infarction, 374
septal, exercise and, 375–376
transient, and hibernating myocardium, 372
and myocardial stunning, 369–370
and thrombolytic therapy, 370–371
disappearance of, after established Q wave myocardial infarction, 372–374
in coronary artery disease, **367–380**
causes of, 368
reappearance of, after coronary bypass surgery, 371–372
transient ischemic, in coronary artery disease, 368–369
QRS complex, during ventricular tachycardia, 12-lead electrocardiogram in, 513, 515–516, 518, 525
QRS voltage, as criterion for left ventricular hypertrophy, 459
Quinidine, in pregnancy, 654
renal considerations and, 681

R wave amplitude, in exercise testing, 188
Radioactive gold, for malignant pericardial disease, 588
Radionuclide angiography, of athletic heart, in exercise, 324–325
Radionuclide lung scanning, to diagnose primary pulmonary hypertension, 566
Radiotherapy, external beam, for malignant pericardial disease, 588–589
Rate of perceived exertion, in exercise testing, 192, 200, 206
beta-blockers and, 207
Renal function, cardiovascular drugs and. See *Cardiovascular drugs.*
Reperfusion, myocardial. See *Myocardial reperfusion.*
Respiratory gas analysis, in exercise testing, 177
Rheumatic heart disease, incidence of thromboembolism in, 597–598
Rifampin, for staphylococcal endocarditis, 550
Right bundle branch block, left anterior fascicular block with, diagnosis of, 476
left ventricular hypertrophy with, 461–462
Q waves and, 374
Roentgenography, chest, to diagnose primary pulmonary hypertension, 566
Romhilt-Estes scoring system, of electrocardiographic criteria, for left ventricular hypertrophy, 456, 457, 458, 460, 461

Saralasin, and exercise, in hypertension, 239
Scintigraphy, thallium-201, to assess coronary thrombolysis, 55, 58, 60–61
Selvester score, to predict infarct size and ventricular function, 435–437
Serum lipids, and exercise training, in coronary artery disease, 216
Serum potassium, and exercise, in hypertension, 236
Shunts, arterial and arteriovenous, thrombosis of, lysis of, 118–120
Sodium nitroprusside, in pregnancy, 665–666
Sodium warfarin, after coronary thrombolysis, 136
Sokolow-Lyon criteria, to detect ventricular hypertrophy, 460–461, 462
Sotalol, in children, clinical experience with, 632–633
ST abnormalities, in myocardial infarction. See *Myocardial infarction.*
ST segment depression, exercise testing and, 186–188
exercise training and, in coronary artery disease, 215–216
isometric exercise and, in myocardial ischemia, 163
isometric exercise training and, in cardiac patients, 166
ST-T wave abnormalities, in myocardial infarction, during ventricular pacing, 415
Staphylococcus aureus, and infective endocarditis, 549–550
Steroids, in lipid metabolism, 287
Streptococci, and infective endocarditis, 547, 549
Streptokinase, clinical pharmacology of, 126
combined intravenous and intracoronary, 82
for arterial and arteriovenous shunt thrombosis, 118–120
for coronary thrombolysis, 13–14, 102
early studies of, 7–10
heparin after, 135–136
practical considerations of, 130, 131
for fibrinolysis, in infective endocarditis, 556
for mural thrombosis, 120–121
for pulmonary embolism, 116–117, 580–581
in fibrin dissolution in vivo, early studies of, 5–6
intracoronary, for coronary thrombolysis, administration protocols for, 80–81
clinical implications of, 88
complications of, 83–84
effect on infarct size and left ventricular function, 84–86
effect on survival, 86–87
efficacy of, 82
pharmacology of, 79–80
reocclusion after, 83
subtotal coronary occlusion and, 81–82
vs. intravenous streptokinase, 87–88
intravenous, for coronary thrombolysis, **91–99**, 106, 107, 131
complications of, 95
documentation of thrombolysis, 92–93
effects on infarct size and ventricular function, 95–96
protocols for administration, 91–92
reinfarction and reocclusion, 93–95
survival statistics, 97–98
vs. heparin, for deep venous thrombosis, 113–115

Stroke volume, and aging heart, in exercise, 333
dynamic exercise and, 149, 158
in coronary artery disease, 152
exercise and, in high altitudes, 252
in hypertension, 234–235
in hyperthermia, 247
exercise training and, in coronary disease patients, 213–214
in normal subjects, 212–213
Stunning, myocardial, transient Q waves and, 369–370
Sudden cardiac death, coronary atherosclerosis and, 23
coronary thrombosis and, 27–28
prevention of, after coronary thrombolysis, 136
Sudden death, exercise and, **337–343**
cardiac pathology in, 340–341
definitions, 337
epidemiology of, 337–338
hypertension in, 315
identification of risk of, 341–342
mechanism of, 338–340
Sulfinpyrazone, for thromboembolism, in prosthetic valves, 609
Superior vena cava syndrome, in malignant pericardial disease, 587

Tachycardia, and athletic heart, in exercise, 327–328
exercise and, in high altitudes, 251
in children, beta-blockers for, 636–637
in Wolff-Parkinson-White syndrome, 12–lead electrocardiogram during, 501, 503
Technetium-99m-pyrophosphate, in infarct imaging, 61–62
Teratogenesis, cardiovascular drugs and, 652
Terbutaline, for primary pulmonary hypertension, 569
Tetanus, in children, beta-blockers for, 643
Tetracycline, intracavitary, for malignant pericardial disease, 588
Tetralogy of Fallot, in children, beta-blockers for, 638–640
Thallium stress testing, protocol for, 185–186
Thallium-201 scintigraphy, to assess coronary thrombolysis, 55, 58, 60–61
Thermoregulation, and exercise, 245–251
Thiazides, pharmacology of, and exercise, 235–236
Thromboembolism, in atrial fibrillation, and cardiomyopathy, 619
and coronary artery disease, 617–618
and heart failure, 618–619
and hypertension, 618
and thyrotoxicosis, 619–620
in mitral valve stenosis and regurgitation, 597–598
Thrombolysis, coronary. See *Coronary thrombolysis.*
Thrombosis, arterial and arteriovenous shunt, lysis of, 118–120
coronary, and coronary atherosclerosis, underlying myocardial infarction. See *Coronary atherosclerosis.*
deep venous. See *Deep venous thrombosis.*
mural, lysis of, 120–121
management of, after coronary thrombolysis, 137
prosthetic valve, lysis of, 117–118, 603–613
Thyrotoxicosis, and atrial fibrillation, thromboembolism in, 619–620
in children, beta-blockers for, 642
Timolol, renal considerations and, 682–683
Timolol maleate, in children, for glaucoma, 643
Tissue-type plasminogen activator (t-PA), for coronary thrombolysis, **101–111**, 15–16, 51
clinical use of, 104–105
in experimental animals, 103–104
pharmacology of, 103, 125–127
practical considerations of, 130, 132
unresolved issues in, 105–106
for deep venous thrombosis, 115
for pulmonary embolism, 117
Tocainide, renal considerations and, 682
Tolazoline, for primary pulmonary hypertension, 569
Tomography, positron-emission, in salvage of jeopardized myocardium, after coronary thrombolysis, 69
to assess coronary thrombolysis, 62–63
Total cholesterol, and exercise, in normolipemic subjects, 292
t-PA. See *Tissue-type plasminogen activator.*
Transient ischemic attacks, and mitral valve prolapse, therapy for, 602–603
Transplantation, heart and lung, for primary pulmonary hypertension, 573
Treadmill exercise, protocols for, 147, 175, 184
Triglycerides, and exercise, in normolipemic subjects, 292
in lipid metabolism, 287
Tumors, pulmonary and breast, and malignant pericardial disease, 583

Ultrasonography, to diagnose pulmonary embolism, 578–579
Urapidil, for primary pulmonary hypertension, 571
Urokinase, for arterial and arteriovenous shunt thrombosis, 119, 120
for coronary thrombolysis, 14–15, 102–103, 104
early studies of, 8–10
practical considerations of, 131–132
for deep venous thrombosis, 115
for pulmonary embolism, 116, 580–581

Valves, prosthetic, and infective endocarditis, 554–555
in valvular heart disease and atrial fibrillation. See *Anticoagulation.*
thrombosis of, lysis of. See *Anticoagulation.*
Valvular heart disease, and exercise testing, 190–191
and isometric exercise, 163–164
Vasculature, coronary, exercise conditioning and, 263–267
Vasodilators, and exercise, in hypertension, 238–239
for primary pulmonary hypertension, 569–573
Vectorcardiography, to diagnose anterior myocardial infarction, 389–390
to diagnose myocardial infarction, 382–384, 384–386, 386–388
Venography, to diagnose pulmonary embolism, 579
Ventilation, evaluation of, in exercise, 172–173
in high altitudes, 252
in exercise testing, 177–179
Ventilation/perfusion lung scanning, to diagnose pulmonary embolism, 578
Ventricular ectopy, exercise and, 188
Ventricular fibrillation, and sudden death, in exercise, 338–339
Ventricular function, exercise and, in hypertension, 312
exercise conditioning and, 261–262
measurement of, in coronary thrombolysis, 59–60, 96
myocardial reperfusion and, 84–86

Ventricular pacing, myocardial infarction during, electrocardiographic diagnosis of. See *Myocardial infarction.*
Ventricular tachycardia, diagnosis of, 12-lead electrocardiogram in, **511–525**
characteristics of wide QRS tachycardia, 511–512
QRS complex during, 513, 515–516, 518, 525
relation of atrium and ventricle in, 512–513
QRS-wave form in, **527–540**
arrhythmogenic right ventricular dysplasia, 530
cardiomyopathies, 530–531
coronary artery disease, 531–535
mitral valve prolapse, 530
paroxysmal sustained ventricular tachycardia, 529–530
repetitive idiopathic ventricular tachycardia, 527–528
Verapamil, for primary pulmonary hypertension, 571
in pregnancy, 659–660
pharmacology of, and exercise, 234
renal considerations and, 683
Warfarin, for anticoagulation, 591–596
action of, 591–593
and hemorrhage, 595–596
optimal prothrombin time in, 593–595
for thromboembolism, in bioprosthetic valves, 611, 612
in prosthetic valves, 606–607
Weight training, in exercise prescription, 202–203
Wolff-Parkinson-White syndrome, electrocardiographic mimickry in, 503–504
Q waves in, 358–360
12-lead electrocardiogram in, **499–509**
diagnosis of presence of accessory pathway, 499–503
during tachycardia, 501, 503
in accessory pathway localization, 507–508
to assess risk of sudden death, 504–506
Xanthine oxidase, production of, in myocardial ischemia and reperfusion, 40–41